デフォルト表紙
市場調査レポート
商品コード
1439961

睡眠補助 - 世界市場の考察、競合情勢、市場予測(2030年)

Sleep Aid - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.94円
睡眠補助 - 世界市場の考察、競合情勢、市場予測(2030年)
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の睡眠補助の市場規模は、2022年に349億6,627万米ドル、2030年までに514億830万米ドルに達し、2024年~2030年の予測期間にCAGRで6.69%の安定した成長が見込まれます。睡眠補助の需要は主に、不眠症、閉塞性睡眠時無呼吸症候群(OSA)、ナルコレプシーなどの睡眠障害の有病率の上昇によって促進されています。また、うつ病、喫煙、飲酒、スクリーンタイムの増加、長時間労働など、睡眠障害の危険因子の増加や、睡眠啓発キャンペーンの増加、製品の発売の増加などが、市場成長を後押ししています。

睡眠補助の市場力学

睡眠補助市場は、うつ病、肥満、喫煙などの睡眠障害の危険因子の増加により製品需要が増加しており、これらが市場の主な市場促進要因となっています。

世界保健機関(WHO)(2022)によると、2019年に全世界で約2億8,000万人(世界人口の3.8%を占める)がうつ病を患っており、そのうち成人5.0%、60歳以上の成人5.7%がうつ病を患っています。多くの調査研究が、睡眠障害と大うつ病の密接な関連性を示しています。うつ病患者は、夜間に入眠し眠り続けることが困難であったり、日中に過度の眠気に襲われることがあります。

World Obesity Federation(2022)が発表したデータによると、2030年までに世界中の約10億人(女性の5人に1人、男性の7人に1人)が肥満とともに暮らすようになると予測されています。過体重や肥満の人は睡眠障害に直面する可能性が高く、閉塞性睡眠時無呼吸症候群のような睡眠障害になりかけています。

人々の睡眠の質に影響を与えるもう1つの大きな要因は、スクリーンタイムの増加と労働時間の増加です。経済協力開発機構(OECD)(2023)によると、2022年の労働者1人当たりの年間平均実働時間は、メキシコ2,128時間、コスタリカ2,073.3時間、コロンビア1,964時間、韓国1,915時間、米国1,791時間、オーストラリア1,694.1時間で、OECD平均の1,687時間を上回っています。長時間労働は睡眠不足を招き、生活の質を低下させます。

同様に、睡眠不足の多発は、携帯電子機器の多用や、寝室でのスクリーンメディア機器の常態化と関連しており、ティーンエイジャーの大半だけでなく、幼児、就学前児童、学齢児童にも影響を及ぼしています。これらの要因は、直接的または間接的に睡眠習慣の悪化に寄与し、結果として主な睡眠障害の発症につながり、最終的に睡眠補助の需要を促進します。

したがって、上記のような睡眠障害の危険因子の症例の増加により、不眠症、OSA、ナルコレプシーなどの有病率が増加し、2024年~2030年の調査期間に睡眠補助市場の成長を促進します。

さらに、新薬の承認などの製品開発活動が、世界の睡眠補助市場の成長をさらに後押しすると予測されます。2020年7月、Jazz PharmaceuticalsのXYWAV®は、ナルコレプシーで起こるカタプレキシーおよび日中の過度の眠気の治療薬として米国FDAに承認されました。

しかし、睡眠薬に伴う副作用や、治療不足につながる睡眠障害の不十分な診断が、睡眠補助機器市場の成長を抑制する可能性があります。

睡眠補助機器市場のセグメント分析

製品タイプセグメントでは、医薬品セグメントが2023年に53.75%の収益シェアを占めると予測されています。これは、ナルコレプシー、不眠症などの睡眠障害の患者に医師が処方するさまざまな睡眠薬の医薬品の広い適用範囲によるものと考えられます。

睡眠薬は、ベンゾジアゼピン系、オレキシン受容体拮抗薬、メラトニン受容体作動薬、抗うつ薬、Z薬などのさまざまな薬剤クラスに分類され、睡眠障害の治療や管理に向けて処方されます。

当レポートでは、世界の睡眠補助市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 睡眠補助市場レポートのイントロダクション

第2章 睡眠補助市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 睡眠補助市場の主な要因の分析

  • 睡眠補助市場の促進要因
  • 睡眠補助市場の抑制要因と課題
  • 睡眠補助市場の機会

第5章 睡眠補助市場のポーターのファイブフォース分析

第6章 睡眠補助市場のレイアウト

  • 製品タイプ
    • 医薬品
    • 睡眠補助機器
  • 用途別
    • 不眠症
    • 閉塞性睡眠時無呼吸症候群(OSA)
    • ナルコレプシー
    • その他
  • 地域
    • 北米の睡眠補助の市場規模(2021年~2030年)
    • 欧州の睡眠補助の市場規模(2021年~2030年)
    • アジア太平洋の睡眠補助の市場規模(2021年~2030年)
    • その他の地域の睡眠補助の市場規模(2021年~2030年)

第7章 睡眠補助市場の企業と製品のプロファイル

  • Pfizer Inc.
  • Idorsia Pharmaceuticals Ltd.
  • Eisai Co., Ltd.
  • Jazz Pharmaceuticals
  • Harmony Biosciences
  • Otsuka Holdings Co., Ltd.
  • Proctor & Gamble
  • Arlak Biotech Pvt. Ltd.
  • Lumiera Health Inc.
  • VedaOils
  • Forest Essentials
  • Neurim Pharmaceuticals LTD

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Sleep Aids Market in Global (2021-2030)
  • Table 3: Sleep Aids Market in Global by Product Type (2021-2030)
  • Table 4: Sleep Aids Market in Global by Application (2021-2030)
  • Table 5: Sleep Aids Market in Global by Geography (2021-2030)
  • Table 6: Sleep Aids Market in North America (2021-2030)
  • Table 7: Sleep Aids Market in North America by Country (2021-2030)
  • Table 8: Sleep Aids Market in the US (2021-2030)
  • Table 9: Sleep Aids Market in Canada (2021-2030)
  • Table 10: Sleep Aids Market in Mexico (2021-2030)
  • Table 11: Sleep Aids Market in Europe (2021-2030)
  • Table 12: Sleep Aids Market in Europe by Country (2021-2030)
  • Table 13: Sleep Aids Market in France (2021-2030)
  • Table 14: Sleep Aids Market in Germany (2021-2030)
  • Table 15: Sleep Aids Market in the United Kingdom (2021-2030)
  • Table 16: Sleep Aids Market in Italy (2021-2030)
  • Table 17: Sleep Aids Market in Spain (2021-2030)
  • Table 18: Sleep Aids Market in the Rest of Europe (2021-2030)
  • Table 19: Sleep Aids Market in Asia-Pacific (2021-2030)
  • Table 20: Sleep Aids Market in Asia-Pacific by Country (2021-2030)
  • Table 21: Sleep Aids Market in China (2021-2030)
  • Table 22: Sleep Aids Market in Japan (2021-2030)
  • Table 23: Sleep Aids Market in India (2021-2030)
  • Table 24: Sleep Aids Market in Australia (2021-2030)
  • Table 25: Sleep Aids Market in South Korea (2021-2030)
  • Table 26: Sleep Aids Market in Rest of Asia-Pacific (2021-2030)
  • Table 27: Sleep Aids Market in the Rest of the World (2021-2030)
  • Table 28: Sleep Aids Market in South America (2021-2030)
  • Table 29: Sleep Aids Market in Africa (2021-2030)
  • Table 30: Sleep Aids Market in the Middle East (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Sleep Aids Market in Global (2021-2030)
  • Figure 3: Sleep Aids Market in Global by Product Type (2021-2030)
  • Figure 4: Sleep Aids Market in Global by Application (2021-2030)
  • Figure 5: Sleep Aids Market in Global by Geography (2021-2030)
  • Figure 6: Sleep Aids Market in North America (2021-2030)
  • Figure 7: Sleep Aids Market in North America by Country (2021-2030)
  • Figure 8: Sleep Aids Market in the US (2021-2030)
  • Figure 9: Sleep Aids Market in Canada (2021-2030)
  • Figure 10: Sleep Aids Market in Mexico (2021-2030)
  • Figure 11: Sleep Aids Market in Europe (2021-2030)
  • Figure 12: Sleep Aids Market in Europe by Country (2021-2030)
  • Figure 13: Sleep Aids Market in France (2021-2030)
  • Figure 14: Sleep Aids Market in Germany (2021-2030)
  • Figure 15: Sleep Aids Market in the United Kingdom (2021-2030)
  • Figure 16: Sleep Aids Market in Italy (2021-2030)
  • Figure 17: Sleep Aids Market in Spain (2021-2030)
  • Figure 18: Sleep Aids Market in the Rest of Europe (2021-2030)
  • Figure 19: Sleep Aids Market in Asia-Pacific (2021-2030)
  • Figure 20: Sleep Aids Market in Asia-Pacific by Country (2021-2030)
  • Figure 21: Sleep Aids Market in China (2021-2030)
  • Figure 22: Sleep Aids Market in Japan (2021-2030)
  • Figure 23: Sleep Aids Market in India (2021-2030)
  • Figure 24: Sleep Aids Market in Australia (2021-2030)
  • Figure 25: Sleep Aids Market in South Korea (2021-2030)
  • Figure 26: Sleep Aids Market in Rest of Asia-Pacific (2021-2030)
  • Figure 27: Sleep Aids Market in the Rest of the World (2021-2030)
  • Figure 28: Sleep Aids Market in South America (2021-2030)
  • Figure 29: Sleep Aids Market in Africa (2021-2030)
  • Figure 30: Sleep Aids Market in the Middle East (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0642

Sleep Aids Market By Product Type (Pharmaceuticals [Prescription, Over The Counter (OTC), Herbal And Dietary Supplements], Sleep Aid Devices), By Application (Insomnia, Obstructive Sleep Apnea (OSA), Narcolepsy And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of sleeping disorders and its associated risk factors such as depression, increased screen time, anxiety, high blood pressure, among others

Global Sleep Aids Market was valued at USD 34,966.27 million in 2022 and is likely to register a CAGR of 6.69% during the forecast period from 2024 to 2030 to reach USD 51,408.30 million by 2030. The demand for sleep aids is primarily being boosted due to the rising prevalence of sleep disorders such as insomnia, obstructive sleep apnea (OSA), narcolepsy, among others. Also, the rising risk factors for sleeping disorders such as depression, smoking, alcohol consumption, increased screen time, longer working hours, among others, and the increase in sleep awareness campaigns coupled with increasing product launches are creating a positive market growth.

Sleep Aids Market Dynamics:

The Sleep Aids market is witnessing a growth in product demand owing to the rising number of risk factors for sleep disorders such as depression, obesity, smoking among others, becoming a major market driver for the Sleep Aids market.

According to the World Health Organization 2022, worldwide around 280 million people, accounting for 3.8% of the global population, including 5.0% adults and 5.7% adults aged 60 years or above, had depression in 2019. The number of research studies have highlighted the close association between sleep disturbances and major depression. Individuals going through depression may find it difficult to fall and stay asleep during the night or experience periods of excessive daytime sleepiness.

The data published by the World Obesity Federation 2022 predicted that by 2030 about 1 billion people around the world, including 1 in 5 women and 1 in 7 men, will be living with obesity. Overweight and obese individuals are more likely to face trouble in sleeping and are at the verge of getting sleep disorders such as obstructive sleep apnea.

Another major factor affecting the sleep quality of people is rise in screen time and increased number of working hours. As per Organization for Economic Co-operation and Development (OECD) 2023, the average annual hours actually worked per worker was 2,128 in Mexico, 2,073.3 in Costa Rica, 1,964 in Colombia, 1,915 in Korea, 1,791 in the US, and 1,694.1 in Australia in 2022, which is higher than the OECD average of 1,687 hours. The longer working hours contribute to lack of sleep and poor quality of life.

Similarly, a high incidence of inadequate sleep is associated with the extensive use of portable electronic devices and the normalization of screen media devices in bedrooms, which affects the majority of teenagers as well as toddlers, preschoolers, and school-age children. These factors directly or indirectly contribute in poor sleeping habits eventually leading to development of major sleeping disorders, ultimately driving the sleep aids demand.

Thus, owing to the increased cases of such risk factors for sleep disorders mentioned above, the prevalence of insomnia, OSA, narcolepsy and others will increase, which will drive the sleep aids market growth during the study period from 2024-2030.

Moreover, product development activities such as approvals for new pharmaceuticals are further expected to aid in the growth of the global Sleep Aids market. In July 2020, XYWAV® by Jazz Pharmaceuticals was approved by the US FDA for the treatment for cataplexy and/or excessive daytime sleepiness that occur in narcolepsy.

However, the side effects associated with sleep medications, under diagnosis of sleep disorders leading to lack of treatment may restrict the sleep aids devices market growth.

Sleep Aids Market Segment Analysis:

Sleep Aids Market by Product Type (Pharmaceuticals [Prescription, Over The Counter (OTC), Herbal And Dietary Supplements], Sleep Aid Devices), Application (Insomnia, Obstructive Sleep Apnea (OSA), Narcolepsy And Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment, the pharmaceuticals segment is expected to have a revenue share of 53.75% in the year 2023. This can be ascribed to the wide applicability of pharmaceuticals for a range of sleep medications are prescribed by doctors to the patients with sleeping disorders such as narcolepsy, insomnia, and others.

The sleep medications belonging to different classes of drug including benzodiazepines, orexin receptor antagonists, melatonin receptor agonists, antidepressants, and Z drugs, are prescribed for the treatment and management of sleep problems.

The major advantage of taking prescription based sleep medications is that these are authorized by the medical experts on the basis of patients overall condition. These drugs are highly regulated and are approved after proper evidence regarding safety and efficacy of the medications. The dosage of medications and its duration is described clearly by the doctors to the patients thereby preventing any kind of misuse or adverse effects. These medications help individuals to fall sleep and stay asleep with minimal or no side effects at all.

For example, QUVIVIQ by Idorsia Pharmaceuticals Ltd. is a prescription medicine for adults who are going through trouble in falling asleep or staying asleep (insomnia). Sonata by Pfizer Inc., is another sleep medicine prescribed by doctors to adults for the short-term treatment of the symptom of trouble falling asleep from insomnia.

Therefore, the various advantages offered by IVUS catheters along with key products for the treatment of sleep disorder management, are predicted to contribute to increase in the overall demand for this product type, thereby driving the growth of the overall sleep aids market during the forecast period.

North America is expected to dominate the overall Sleep Aids Market:

Among all the regions, North America is expected to hold the largest share of 40.12% in the sleep aids market in 2022. This can be ascribed to the increasing prevalence of mental illness and sleep disorders such as depression, anxiety, insomnia, obstructive sleep apnea, among others. In addition, the increasing figures of risk factors affecting sleep quality such as obesity, stress, and others will influence the growth of the sleep aids in the North America region.

For instance, as per the National Center for Health Statistics under Centers for Disease Control and Prevention (CDC) 2022, about 14.5% of adults in the country faced trouble in falling asleep and around 17.8% of adults had trouble staying asleep in 2020.

The Sleep Foundation, in a latest study concluded that 35.2% of adults reported sleeping on an average for less than seven hours per night. However, seven to nine hours sleep per night is ideal for most adults, lack of which might lead to many sleeping disorders, ultimately increasing the demand of various sleep aids such as sedative, hypnotics, hormonal sprays, and others. The afore-said source stated that obstructive sleep apnea (OSA), affects 2-9% of adults in the United States.

According to latest data by CDC, about 8.4% of US adults took sleep medication in the last 30 days either every day or most days to help them fall or stay asleep.

Further, the increasing strategic activities such as approvals, launches, acquisitions, mergers, partnerships, among others will increase the overall market in the country.

For instance, in January 2022, Idorsia Ltd announced the US Food and Drug Administration (FDA) approval for QUVIVIQ(TM) (daridorexant) which is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Thus, the increasing prevalence of sleep related issues such as reduced sleep hours, late sleep, among others, along with product launches will increase the demand for sleep aids in the North American region, during the forecast period from 2024-2030.

Sleep Aids Market Key Players:

Some of the key market players operating in the Sleep Aids market include Pfizer Inc., Idorsia Pharmaceuticals Ltd., Eisai Co., Ltd., Jazz Pharmaceuticals, Harmony Biosciences, Otsuka Holdings Co., Ltd., Procter & Gamble, Arlak Biotech Pvt. Ltd., Lumiera Health Inc, VedaOils, Forest Essentials, Neurim Pharmaceuticals LTD, and others.

Recent Developmental Activities in the Sleep Aids Market:

In February 2023, Arlak Biotech announced the launch of Superior Quality Arlak Melatonin Spray that offers convenient and efficient supplementation of body's natural melatonin production for better sleep in India.

In August 2022, Vivos Therapeutics received 510(k) market clearance from the US FDA for its mmRNA (modified mandibular Repositioning Nighttime Appliance) device to treat mild to moderate obstructive sleep apnea (OSA).

In June 2020, Noctrix Health, Inc., a privately held medical device company announced that it has received Breakthrough Device Designation for its wearable NTX100 Neuromodulation therapy from the US Food and Drug Administration (FDA). The device is designed for the treatment of adults with primary moderate-severe restless legs syndrome (RLS) who are refractory to medications.

Key Takeaways from the Sleep Aids Market Report Study

Market size analysis for current sleep aids market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the Global sleep aids Market.

Various opportunities available for the other competitor in the sleep aids market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current sleep aids market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for sleep aids market growth in the coming future?

Target Audience who can be benefited from this Sleep Aids Market Report Study

Sleep aids products providers

Research organizations and consulting companies

Sleep aids-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in sleep aids

Various end-users who want to know more about the sleep aids market and the latest technological developments in the sleep aids market.

Frequently Asked Questions for the Sleep Aids Market:

1. What are sleep aids?

Sleep aids include pharmaceuticals, sleep aid devices, mattresses and pillows, among others that are effective for the treatment of sleep disorders. They are meant for the treatment and management of a range of sleep disorders including insomnia, OSA, restless leg syndrome, narcolepsy, and many others.

2. What is the market for Global Sleep Aids?

The global sleep aids market was valued at USD 34,966.27 million in 2022 and is likely to register a CAGR of 6.69% during the forecast period from 2024 to 2030 to reach USD 51,408.30 million by 2030.

3. What are the drivers for Global Sleep Aids Market?

The demand for sleep aids is primarily being boosted due to the rising prevalence of sleep disorders such as insomnia, obstructive sleep apnea (OSA), narcolepsy, among others. Also, the rising risk factors for sleeping disorders such as depression, smoking, alcohol consumption, increased screen time, longer working hours, among others, and the increase in sleep awareness campaigns coupled with increasing product launches are expected to create a positive market growth during the forecast period 2024-2030.

4. Who are the key players operating in Global Sleep Aids Market?

Some of the key market players operating in the Sleep Aids market include Pfizer Inc., Idorsia Pharmaceuticals Ltd., Eisai Co., Ltd., Jazz Pharmaceuticals, Harmony Biosciences, Otsuka Holdings Co., Ltd., Procter & Gamble, Arlak Biotech Pvt. Ltd., Lumiera Health Inc, VedaOils, Forest Essentials, Neurim Pharmaceuticals LTD, and others.

5. Which region has the highest share in the Sleep Aids market?

North America is expected to dominate the overall sleep aids market during the forecast period from 2024-2030. This can be ascribed to the increasing prevalence of mental illness and sleep disorders such as depression, anxiety, insomnia, obstructive sleep apnea, among others. In addition, the increasing figures of risk factors affecting sleep quality such as obesity, stress, and others will influence the growth of the sleep aids in the North America region.

Table of Contents

1. Sleep Aids Market Report Introduction

2. Sleep Aids Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Sleep Aids Market Key Factors Analysis

  • 4.1. Sleep Aids Market Drivers
    • 4.1.1. Growing prevalence of sleep disorders and risk factors affecting sleep habits and quality
    • 4.1.2. Surge in sleep awareness campaigns highlighting the benefit of sleep quality
    • 4.1.3. Availability of non-invasive treatment options
  • 4.2. Sleep Aids Market Restraints and Challenges
    • 4.2.1. Side effects associated with sleep medications
    • 4.2.2. Under diagnosis of sleep disorders leading to lack of treatment
  • 4.3. Sleep Aids Market Opportunities
    • 4.3.1. Growing concept of precision sleep medicine
    • 4.3.2. Improving drug delivery of melatonin with nanotechnology

5. Sleep Aids Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Sleep Aids Market Layout

  • 6.1. By Product Type
    • 6.1.1. Pharmaceuticals
      • 6.1.1.1. Prescription
      • 6.1.1.2. Over the Counter (OTC)
      • 6.1.1.3. Herbal and Dietary Supplements
    • 6.1.2. Sleep Aid Devices
  • 6.2. By Application
    • 6.2.1. Insomnia
    • 6.2.2. Obstructive Sleep Apnea (OSA)
    • 6.2.3. Narcolepsy
    • 6.2.4. Others
  • 6.3. By Geography
    • 6.3.1. North America Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.1.1. United States Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.1.2. Canada Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.1.3. Mexico Sleep Aids Market Size in USD million (2021-2030)
    • 6.3.2. Europe Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.2.1. France Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.2.2. Germany Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.2.3. United Kingdom Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.2.4. Italy Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.2.5. Spain Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.2.6. Rest of Europe Sleep Aids Market Size in USD million (2021-2030)
    • 6.3.3. Asia-Pacific Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.3.1. China Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.3.2. Japan Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.3.3. India Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.3.4. Australia Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.3.5. South Korea Sleep Aids Market Size in USD million (2021-2030)
      • 6.3.3.6. Rest of Asia-Pacific Sleep Aids Market Size in USD million (2021-2030)
    • 6.3.4. Rest of the World (RoW) Sleep Aids Market Size in USD million (2021-2030)
      • 7.3.4.1. South America Sleep Aids Market Size in USD million (2021-2030)
      • 7.3.4.2. Africa Sleep Aids Market Size in USD million (2021-2030)
      • 7.3.4.3. Middle East Sleep Aids Market Size in USD million (2021-2030)

7. Sleep Aids Market Company and Product Profiles

  • 7.1. Pfizer Inc.
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Idorsia Pharmaceuticals Ltd.
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Eisai Co., Ltd.
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Jazz Pharmaceuticals
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. Harmony Biosciences
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Otsuka Holdings Co., Ltd.,
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Proctor & Gamble
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Arlak Biotech Pvt. Ltd.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Lumiera Health Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. VedaOils
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Forest Essentials
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Neurim Pharmaceuticals LTD
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us